LEO Pharma A/S

LEO Pharma is a global pharmaceutical company dedicated to advancing the standard of care for people with skin conditions. Founded in 1908, the company specializes in medical dermatology, focusing on research, development, and marketing of innovative treatments. Its mission is to help people achieve healthy skin by advancing the science of dermatology, improving patient care, and providing access to effective therapies worldwide. LEO Pharma's headquarters are located in Ballerup, near Copenhagen, Denmark.

The company's portfolio includes a wide range of prescription medications and over-the-counter products for various skin conditions, such as psoriasis, eczema (atopic dermatitis), skin infections, and rare skin diseases. Key products include Adtralza®/Adbry® (tralokinumab) for atopic dermatitis, Enstilar® for psoriasis, the Fucidin® range, Protopic® (tacrolimus ointment), and Anzupgo® (delgocitinib) for chronic hand eczema. LEO Pharma is also actively developing new therapies, with a pipeline that includes TMB-001 for Congenital Ichthyosis and a recently acquired gene therapy platform from Replay targeting genetic skin diseases like dystrophic epidermolysis bullosa.

Christophe Bourdon serves as the CEO, having been appointed in April 2022, and is leading the company's strategic transformation to enhance its position in medical dermatology. LEO Pharma has been expanding its pipeline through strategic acquisitions, including key assets from Timber Pharmaceuticals in January 2024 and the gene therapy company Replay in April 2026, to bolster its focus on rare dermatological diseases. The company reported a 10% revenue growth in 2025 and is working towards a potential public listing.